[Our regions evaluate the program. Contraception by injectable progestin, Depo Provera: opportunity, continuity and analyses of the situation in central west Tunisia].
Khelifi
A
A
D000349:Africa; D000352:Africa, Northern; D003267:Contraception; D003268:Contraception Behavior; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003906:Developing Countries; D005193:Family Planning Services; D007267:Injections; D017258:Medroxyprogesterone Acetate; D008877:Middle East; D010342:Patient Acceptance of Health Care; D012106:Research; D012189:Retrospective Studies; D014416:Tunisia
D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D017258:Medroxyprogesterone Acetate
Africa; Arab Countries; Contraception; Contraception Termination; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Contraceptive Methods--side effects; Contraceptive Usage; Depo-provera--side effects; Developing Countries; Family Planning; French Speaking Africa; Injectables--side effects; Mediterranean Countries; Medroxyprogesterone Acetate--side effects; Method Acceptability; Northern Africa; Research Methodology; Retrospective Studies; Studies; Tunisia